New 'cocktail' drug could benefit up to 45 per cent of patients with Duchenne muscular dystrophy

A new 'cocktail' drug under development could provide an effective and economical treatment to lessen symptoms for up to 45 per cent of patients with Duchenne muscular dystrophy (DMD), a chronic muscle-wasting disease.